The impact of sarcopenia on the efficacy of PD-1 inhibitors in non-small cell lung cancer and potential strategies to overcome resistance
Recent studies have revealed that sarcopenia can adversely affect the efficacy of PD-1 inhibitors in the treatment of non-small cell lung cancer (NSCLC). PD-1 inhibitors are immune checkpoint inhibitors widely used in the treatment of various cancers. However, NSCLC patients may have poorer outcomes...
Saved in:
Main Authors: | Zhenchao Liu (Author), Tianxiang Lei (Author), Yunliang Guo (Author), Chongwen Zheng (Author) |
---|---|
Format: | Book |
Published: |
Frontiers Media S.A.,
2024-07-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
PD0325901, an ERK inhibitor, enhances the efficacy of PD-1 inhibitor in non-small cell lung carcinoma
by: Min Luo, et al.
Published: (2021) -
Targeting immune cell types of tumor microenvironment to overcome resistance to PD-1/PD-L1 blockade in lung cancer
by: Man Wang, et al.
Published: (2023) -
MET Inhibitor is Expected to Overcome MET Amplification-Induced Immunotherapy Resistance in Non-Small Cell Lung Cancer
by: Ji Ruan
Published: (2021) -
The new concepts on overcoming drug resistance in lung cancer
by: Zhang W, et al.
Published: (2014) -
Pharmacoeconomic efficacy of atesolizumab compared with other PD-1 inhibitors in patients with advanced non-small cell lung cancer after chemotherapy
by: S. K. Zyryanov, et al.
Published: (2020)